Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.01
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-2.3M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$70M
P/E
N/A
•EV/EBITDA
16.1x
↑ROE
39.0%
↑Gross Margin
45.6%
↓Debt/Equity
-2.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.1%
FCF CAGR
—
FCF margin
-14.4%
FCF / Net income
0.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $144.0M · net income $-40.2M · FCF $-20.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $144.0M | $144.0M | $167.6M | $159.2M | $163.2M |
| Net Income | $-40.2M | $-40.2M | $-7.6M | $-76.6M | $-449.4M |
| EBITDA | $17.6M | $17.6M | $21.2M | $-2.6M | $-380.7M |
| EPS | -0.01 | -0.01 | — | -0.01 | -0.13 |
| Gross Margin | 45.6% | 45.6% | 44.8% | 39.7% | 45.6% |
| Operating Margin | -8.5% | -8.5% | -5.7% | -18.0% | -40.3% |
| Net Margin | -27.9% | -27.9% | -4.6% | -48.1% | -275.3% |
| Balance Sheet | |||||
| Debt/Equity | -2.21 | -2.21 | -3.21 | -3.26 | 16.74 |
| Current Ratio | 0.70 | 0.70 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-20.8M | $-20.8M | $6.8M | $-2.3M | $-26.5M |
| Returns | |||||
| ROE | 39.0% | 39.0% | 11.7% | 124.3% | -4089.5% |
| Valuation | |||||
| EV/EBITDA | 16.08 | 16.08 | 12.13 | — | — |
| P/B | — | — | — | — | 9.20 |
| Growth & Yield | |||||
| Revenue Growth | -14.1% | -14.1% | 5.2% | -2.4% | — |
| EPS Growth | — | — | — | 92.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+100.0%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → -0.01
Residual
+100.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.